Summary of Study ST000492

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST000492
Study Title	Sleep apnea and cardiovascular samples ceramide concentrations
Study Summary	Sleep apnea and cardiovascular samples ceramide concentrations
Institute	Mayo Clinic
Laboratory	Mayo Clinic Metabolomics Resource Core
Last Name	Pak
First Name	Victoria
Address	unknown
Email	victoria.pak@yale.edu
Phone	203-737-5065
Submit Date	2016-10-14
Analysis Type Detail	LC-MS
Release Date	2018-10-10
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000370
Project DOI:	doi: 10.21228/M87604
Project Title:	Mayo Metabolomics Pilot and Feasibility Award: Mechanisms of sleep apnea and cardiovascular disease
Project Type:	MS targeted analysis
Project Summary:	Targeted Metabolic and Biological Markers of Sleepiness Symptoms in Sleep apnea and cardiovascular disease
Institute:	Mayo Clinic
Laboratory:	Mayo Clinic Metabolomics Resource Core
Last Name:	Pak
First Name:	Victoria
Address:	unknown
Email:	victoria.pak@yale.edu
Phone:	203-737-5065

Subject:

Subject ID:	SU000513
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Species Group:	Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Disease
SA025536	ms5687-12	cardiovascular disease
SA025537	ms5687-11	cardiovascular disease
SA025538	ms5687-14	cardiovascular disease
SA025539	ms5687-16	cardiovascular disease
SA025540	ms5687-1	cardiovascular disease
SA025541	ms5687-10	cardiovascular disease
SA025542	ms5687-15	cardiovascular disease
SA025543	ms5687-13	cardiovascular disease
SA025544	ms5687-3	cardiovascular disease
SA025545	ms5687-9	cardiovascular disease
SA025546	ms5687-2	cardiovascular disease
SA025547	ms5687-4	cardiovascular disease
SA025548	ms5687-5	cardiovascular disease
SA025549	ms5687-8	cardiovascular disease
SA025550	ms5687-7	cardiovascular disease
SA025551	ms5687-6	cardiovascular disease
SA025552	ms5687-31	sleep apnea
SA025553	ms5687-30	sleep apnea
SA025554	ms5687-29	sleep apnea
SA025555	ms5687-32	sleep apnea
SA025556	ms5687-36	sleep apnea
SA025557	ms5687-28	sleep apnea
SA025558	ms5687-35	sleep apnea
SA025559	ms5687-34	sleep apnea
SA025560	ms5687-33	sleep apnea
SA025561	ms5687-19	sleep apnea
SA025562	ms5687-21	sleep apnea
SA025563	ms5687-20	sleep apnea
SA025564	ms5687-18	sleep apnea
SA025565	ms5687-17	sleep apnea
SA025566	ms5687-22	sleep apnea
SA025567	ms5687-23	sleep apnea
SA025568	ms5687-26	sleep apnea
SA025569	ms5687-25	sleep apnea
SA025570	ms5687-24	sleep apnea
SA025571	ms5687-27	sleep apnea

Showing results 1 to 36 of 36

Showing results 1 to 36 of 36

Collection:

Collection ID:	CO000507
Collection Summary:	For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core via LC-MS/MS for simultaneous detection and quantification of metabolites for analyses.
Sample Type:	Blood

Treatment:

Treatment ID:	TR000527
Treatment Summary:	Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Treatment ID:

TR000527

Treatment Summary:

Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Sample Preparation:

Sampleprep ID:	SP000520
Sampleprep Summary:	ceramide concentrations

Combined analysis:

Analysis ID	AN000758
Analysis type	MS
Chromatography type	HILIC
Chromatography system	Waters Acquity
Column	AMT HALO HILIC 2 (150 x 4.6mm,2.7um)
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	Thermo Quantiva QQQ
Ion Mode	POSITIVE
Units	micromolar

Chromatography:

Chromatography ID:	CH000544
Instrument Name:	Waters Acquity
Column Name:	AMT HALO HILIC 2 (150 x 4.6mm,2.7um)
Chromatography Type:	HILIC

MS:

MS ID:	MS000670
Analysis ID:	AN000758
Instrument Name:	Thermo Quantiva QQQ
Instrument Type:	Triple quadrupole
MS Type:	ESI
Ion Mode:	POSITIVE